Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renal effects of empagliflozin with or without semaglutide in type 2 diabetes with albuminuria
2019-003175-19Phase 4Completed
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in type 2 diabetes mellitus (T2DM) and diabetic glomerulosclerosis comparing Empagliflozin + Semaglutide with Empagliflozin + Placebo (2 arms). Primary endpoint: Change in albuminuria (UACR). Started Oct 2019; status: completed.
02
Drugs
semaglutideempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosis
Beyond the preview
Go deeper on 2019-003175-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003175-19.